Synta Pharmaceuticals: 4 Key Investing Takeaways From 2013

2013 was a rough year for Synta Pharmaceuticals (NASDAQ: SNTA  ) , which lost more than 50% of its market value since the beginning of the year. The company, which focuses on developing small molecule drugs for cancer and inflammatory diseases, took investors on a year-long roller coaster ride, hitting a 52-week high of $11.88 in January before diving to a low of $3.70 in November.

SNTA Chart

Source: YCharts.

Synta has one main drug, ganetespib, in clinical trials. This drug belongs to a new class of drugs known as Hsp90 (heat shock protein 90) inhibitors. Hsp90 plays a role in the maturation of client proteins, which help cells growth, divide, and survive. Compared to healthy cells, cancer cells are more dependent on elevated levels of Hsp90 to proliferate -- therefore, inhibiting the production of Hsp90 could stop certain types of cancer.

Unlike other targeted therapies which seek out specific mutations, such as Pfizer's Xalkori or Roche's (NASDAQOTH: RHHBY  ) Herceptin, Hsp90 inhibitors are believed to be able to disrupt several signaling pathways simultaneously to stop tumor cell proliferation.

Synta is primarily focusing on developing ganetespib as a treatment for non-small-cell lung cancer, or NSCLC, and breast cancer. If approved, the drug is expected to hit annual peak sales of $450 million to $500 million.

Let's take a look at four key investing takeaways from Synta's very volatile year.

1. Synta is an all-in bet on the success of Hsp90
The big challenge for Synta is proving that Hsp90 inhibitors are actually a feasible cancer treatment. Let's take a look at the current status of some other Hsp90 inhibitors.

Company

Drug

Status

Infinity Pharmaceuticals (NASDAQ: INFI  )

Retaspimycin HCI

Terminated after failed NSCLC trial

Exelixis

XL888

Suspended

Biogen

BIIB021, BIIB028

Suspended

Myrexis

MPC-3100, MPC-0767

Suspended

Astex Pharmaceuticals

AT13387

Phase 2

Novartis/Vernalis

AUY922

Phase 2

Debiopharm/Curis

Debio 0932

Phase 1/2

Kyowa Hakko Kirin

KW2478

Phase 1/2

Samus Therapeutics

PU-H71

Phase 1

Esanex

SNX-5422

Restarted

Source: Hsp90central.com

Considering the rate of suspensions and failures, the risk that Synta faces becomes clear -- it's one of the only publicly traded companies that has placed an all-in bet on the success of Hsp90 inhibitors.

2. Trials and tribulations for its pipeline
Four clinical trials -- two for NSCLC and two for breast cancer -- are the keys to unlocking ganetespib's growth potential.

Cancer

Trial

Trial Name

Tested Indication

NSCLC

Phase 2

GALAXY-2

Second-line treatment with chemotherapy

 

Phase 2b/3

GALAXY-1

First-line treatment with chemotherapy

Breast cancer

Phase 2b/3 (TBA)

ENCHANT-2

First-line treatment for HER2 negative, metastatic breast cancer with chemotherapy

 

Phase 2

ENCHANT-1

First-line treatment for metastatic breast cancer with chemotherapy

Source: Company website.

Over the past year, however, optimism has faded, due to several factors. In June, Synta reported that during the GALAXY-1 study, patients given ganetespib showed a median survival rate of 9.8 months, compared to 7.4 months for the group only given chemotherapy. However, the drug only reduced the risk of death by 18%, far lower than the company's original projection of 31% in October 2012. As a result, the stock plunged 34% -- its steepest decline in four years.

In September 2013, Infinity's Retaspimycin HCI was terminated, casting even more doubts on the future of Hsp90 inhibitors as a viable treatment for NSCLC. Retaspimycin was intended to treat squamous cell carcinoma, a type of NSCLC commonly caused by smoking.

Synta's one-year follow-up for GALAXY-1 the following month was positive, however -- it reported that patients had an overall survival rate of 65%, with a survival rate of 10.7 months compared to 7.4 months on chemotherapy alone. However, there were concerns about vast differences in enrollment and treatment patterns across testing centers, which Synta admitted could have affected the study.

An additional offering of an 16.1 million shares in November, aimed at boosting the company's light cash position of $53.4 million, has caused the stock to slide over 30% since late October. However, Synta reported proceeds of $60.4 million from the sale, prior to the deduction of underwriting discounts, commissions, and other expenses.

3. Brighter days ahead?
Despite all these challenges, there is a silver lining on these storm clouds -- Synta recently reported positive interim results from its ENCHANT-1 trial of ganetespib as a breast cancer treatment for HER2+ patients and triple-negative breast cancer, or TNBC, patients.

Synta stated that 3 out of 4 HER2+ (75%) patients achieved an objective response with ganetespib monotherapy, with one patient experiencing a radiologic complete response. Meanwhile, 7 out of 11 (64%) TNBC patients achieved disease control with ganetespib monotherapy. 7 out of 15 (47%) HER2+ and TNBC patients also showed a rapid metabolic response.

This was the second bit of encouraging news regarding ENCHANT-1 that investors received this year. The first announcement, a similarly positive outcome for its phase 1 study, caused shares to spike 45% at the end of July.

In other words, Synta appears to have a brighter future in breast cancer than in NSCLC. However, investors shouldn't get ahead of themselves yet -- the ENCHANT-1 trial group is very small, and percentages could significantly shift as it progresses into a larger phase 3 study.

4. Lack of interest from big pharma
In my opinion, Roche's lack of interest in Hsp90 is also troubling. Roche, the largest cancer drug company in the world, is well known for investing in promising new oncology treatments, such as ImmunoGen's antibody-drug conjugates (also known as "cancer smart bombs"), Halozyme's Enhanze technology (which turns IV drips into quick-acting shots), Inovio's cancer vaccines, Curis' signaling pathway technology, and many others -- but it has no known interest in Hsp90 inhibitors. In fact, Novartis is the only large pharmaceutical company developing an Hsp90 inhibitor.

Five years ago, Synta had a major partner, GlaxoSmithKline (NYSE: GSK  ) , which believed that its melanoma drug would be a potential blockbuster. Instead, the drug failed a phase 3 trial in 2009 after more people died taking Synta's drug than the standard treatment. Today, Synta no longer has any major backers -- which should be a clear warning that the company still has a lot to prove.

The Foolish takeaway
In conclusion, Synta is a volatile, all-in bet on an unproven technology.

The termination of Infinity's Hsp90 drug and the suspension of higher profile ones from Biogen and Exelixis are troubling. In addition, the constant changes to the projected reduction of death in NSCLC patients during GALAXY-1 urge me to take its initially impressive ENCHANT-1 results with a grain of salt.

Synta could bounce back in 2014, but it has to get a lot of things right. Investors should pay attention to the overall status of Hsp90 drugs and the interest of larger pharmaceutical companies, which could indicate if ganetespib has a promising future ahead.

Check out this big growth stock instead
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.


Read/Post Comments (4) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 20, 2013, at 10:36 PM, HuiyiChen wrote:

    If the company flips, an investor could lose up to 100% on their SNTA investment, however if the company succeeds, the investment could triple or quadruple. So presumably it all depends on how one perceive the likelyhood of Synta's success. Personaly I bought very little of SNTA below $4.5, besides major stake on TSLA, NUAN, ATHM, AMAVF, CF, CVI, TJX, TOL, LBTYA, CBS. SNTA seems an odd bird on my portfolio. Worse, Synta went into phase III trial before phase II ended, statistically that increases its chance to fail eight fold. Yet, the insider purchases are hard to ignore. We have less information on Synta's research progress than its CEO, less information on Synta's 2014 finance prospect than Bruce Kovnor, if those guys are putting 200k or 100m(Caxton is at least 6.4b), one probably could have a bit of faith and invest 3% of one's money on SNTA? After all it's the best in its field and research on cancer cure has been quite a while.

  • Report this Comment On December 21, 2013, at 4:54 AM, TMFSunLion wrote:

    Synta is risky, but I think a small, speculative investment on it wouldn't be a terrible idea.

    It's just that it absolutely needs Hsp90 to work, and the ENCHANT-1 group, in my opinion, is still too small, if we consider what happened to GALAXY-1.

    I really want to see more interest from big pharma in Hsp90, though, before I can be more confident in Synta's prospects.

  • Report this Comment On December 29, 2013, at 5:07 AM, HuiyiChen wrote:

    Thank you. I really appreciate the information.

    Indeed, the inhibitor really has to work. Teva is probably a safer play in pharmaceuticals.

  • Report this Comment On January 01, 2014, at 9:12 PM, Bowoofer wrote:

    Well written piece. The review of other HsP inhibitors is very helpful and insightful.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2768948, ~/Articles/ArticleHandler.aspx, 10/30/2014 1:08:25 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement